Heparin-induced thrombocytopenia: What clinicians need to know

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Thrombosis and Haemostasis

• Publication date

  2009-01-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH08-10-0659PMID 19190810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Decision Making And Problem Solving

  2014influential reference
• Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.

  2008cited by this paper
• Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779–781)

  2008cited by this paper
• Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)

  2008cited by this paper
• Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin “flushes”

  2007cited by this paper
• Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin

  2007cited by this paper
• Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories

  2007cited by this paper
• Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia

  2007cited by this paper
• Heparin-induced thrombocytopenia (HIT)

  2006cited by this paper
• Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.

  2005cited by this paper
• Heparin-induced thrombocytopenia.

  2003cited by this paper
• Laboratory diagnosis of immune heparin-induced thrombocytopenia.

  2003cited by this paper
• Heparin‐induced thrombocytopenia and thrombosis syndrome: in vivo cross‐reactivity with danaparoid and successful treatment with r‐Hirudin

  2001cited by this paper
• A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia

  2001cited by this paper
• Prospective Randomised Open-label Comparison of Danaparoid with Dextran 70 in the Treatment of Heparin-induced Thrombocytopaenia with Thrombosis

  2001cited by this paper
• Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.

  2000cited by this paper
• Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies.

  1991cited by this paper

• Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments

  2024cites this paper
• Highlighting the versatility of the citrullination process.

  2022cites this paper
• NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia

  2021cites this paper
• Clinical Appearance and Diagnosis of Heparin Induced Thrombocytopenia

  2021cites this paper
• Inhibition of NADPH oxidase blocks NETosis and reduces thrombosis in heparin-induced thrombocytopenia

  2021cites this paper
• Heparanase and Type 1 Diabetes.

  2020cites this paper
• Evolving concepts of pathogenesis of heparin‐induced thrombocytopenia: Diagnostic and therapeutic implications

  2020cites this paper
• Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics

  2019cites this paper
• Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia

  2019cites this paper
• Right Ventricular Thrombosis Combined With Fetal Death and Acrocyanosis in Pregnancy.

  2017cites this paper
• Drug-Induced Thrombocytopenia: Pathogenesis, Diagnosis and Management

  2017cites this paper
• Trends in the development of oral anticoagulants.

  2015cites this paper
• An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions

  2014cites this paper
• Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry.

  2014cites this paper
• HIT: nucleic acid masquerading as heparin.

  2013cites this paper
• Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)

  2013cites this paper
• Drug-induced immune thrombocytopenia.

  2013cites this paper
• Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: a retrospective study.

  2013cites this paper
• Managing heparin infusions.

  2012cites this paper
• Impact of bivaluridin and Genous stent in patients with acute myeloid leukemia undergoing emergency percutaneous coronary angioplasty for acute coronary syndrome

  2012cites this paper
• Evaluation of appropriate serologic testing for suspected heparin-induced thrombocytopenia.

  2012cites this paper
• Drug-induced thrombocytopenia: MIBS trumps LIBS.

  2012cites this paper
• Thrombin as a multi-functional enzyme

  2011cites this paper
• Trombocitopenia inducida por enoxaparina con trombosis arterial y venosa acompañante

  2011cites this paper
• [Enoxaparin-induced thrombocytopenia with associated arterial and venous thrombosis].

  2011cites this paper
• Heparin-induced thrombocytopenia: what a vascular surgeon needs to know.

  2011cites this paper
• An approach to the patient with retiform purpura

  2011cites this paper
• Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia

  2010cites this paper
• Update on heparin: what do we need to know?

  2010cites this paper
• La thrombocytose au cours des traitements par héparine de bas poids moléculaire: une situation plus fréquente qu'on ne le croit?

  2010cites this paper
• [Thrombocytosis in patients treated with low-molecular-weight heparin: more common than imagined?].

  2010cites this paper
• Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia

  2010cites this paper
• Bivalirudin: a review of the pharmacology and clinical application

  2010cites this paper
• Heparin-Induced Thrombocytopenia (HIT): A Case Study

  2010cites this paper
• Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue

  2010cites this paper
• Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty

  2009cites this paper
• Chasing clot: thrombophilic states and the interventionalist.

  2009cites this paper